ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2025
Association of Inherited Genetic Variants with Multiple Primary Melanoma.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
23 authors.
David C GibbsDepartment of Dermatology, Emory University, Atlanta, Georgia.ORCID 0000-0001-7813-6272
Brittany M SmallDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0003-3264-3318
Isidora AutuoriDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-0288-8416
Siok F LeongDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0011-3999
Emily AliDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0009-0004-9372-0679
Jessica KenneyDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-2475-8580
Li LuoDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico.ORCID 0000-0003-0728-8628
Peter A KanetskyDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida.ORCID 0000-0002-5567-9618
Klaus J BusamDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-0888-9601
Anne E CustThe Daffodil Centre, The University of Sydney, a Joint Venture with Cancer Council NSW, Sydney, Australia.ORCID 0000-0002-5331-6370
Hoda Anton-CulverDepartment of Epidemiology, University of California, Irvine, California.ORCID 0000-0002-9603-0110
Richard P GallagherCancer Control Research, British Columbia Cancer and Department of Dermatology and Skin Science, University of British Columbia, Vancouver, Canada.ORCID 0000-0003-2365-0391
Roberto ZanettiPiedmont Cancer Registry, Center for Cancer Prevention, Torino, Italy.ORCID 0000-0001-6498-4086
Stefano RossoPiedmont Cancer Registry, Center for Cancer Prevention, Torino, Italy.ORCID 0000-0001-6816-2661
Lidia SacchettoPiedmont Cancer Registry, Center for Cancer Prevention, Torino, Italy.ORCID 0000-0001-6590-325X
Sharon N EdmistonDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0001-8273-446X
Kathleen ConwayDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-5540-3347
David W OllilaLineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0003-4129-6808
Colin B BeggDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-3772-1795
Marianne BerwickDepartment of Internal Medicine, University of New Mexico Cancer Center, University of New Mexico, Albuquerque, New Mexico.ORCID 0000-0001-5062-2180
Irene OrlowDepartment of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0001-6234-6961
Nancy E ThomasDepartment of Dermatology, University of North Carolina, Chapel Hill, North Carolina.ORCID 0000-0002-2230-1328
GEM Study Group
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
UNC-CH CENTER FOR ENVIRONMENTAL HEALTH &SUSCEPTIBILITYP30ES010126 · NIEHS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Hazel B Nichols · 2001 to 2026
$36.3M
Sex Differences in Methylome Alterations and Mutational Burden in Early Stage MelanomaP01CA206980 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI BERWICK, MARIANNE, THOMAS, NANCY E. · 2017 to 2022
$10.1M
Melanoma RAS/BRAF Mutation:Heterogeneity-Risk-PrognosisR01CA112243 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI THOMAS, NANCY E. · 2005 to 2014
$5.4M
A MODEL FOR GENETIC SUSCEPTIBILITY: MELANOMAU01CA083180 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 1999 to 2003
$5.2M
Identification of Lethal Melanomas at the Time of DiagnosisR01CA233524 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI ANTON-CULVER, HODA A, BEGG, COLIN B · 2020 to 2024
$4.5M
Solar Exposure and Melanoma SurvivalR01CA112524 · NCI · UNIVERSITY OF NEW MEXICO · PI BERWICK, MARIANNE · 2005 to 2009
$2.5M
Epidemiologic Parameters of Rare Cancer Risk FactorsR01CA098438 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI BEGG, COLIN B · 2003 to 2005
$839k
Validation of the use of whole-genome amplified DNA in a population-based studyR03CA173806 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ORLOW, IRENE · 2013 to 2014
$170k
Mutational Analysis of Clonality in Multiple Primary MelanomaR03CA125829 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ORLOW, IRENE · 2006 to 2007
$128k
Melanoma Centre of Research Excellence (Melanoma CRE) 2008454National Cancer Institute (NCI) P01CA206980National Cancer Institute (NCI) P30CA016086National Cancer Institute (NCI) R01CA098438National Cancer Institute (NCI) R01CA112243National Cancer Institute (NCI) R01CA233524National Cancer Institute (NCI) R03CA125829National Cancer Institute (NCI) U01CA83180NCI NIH HHS P01 CA206980NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016086NCI NIH HHS R01 CA098438NCI NIH HHS R01 CA112243NCI NIH HHS R01 CA112524NCI NIH HHS R01 CA233524NCI NIH HHS R03 CA125829NCI NIH HHS R03 CA173806NCI NIH HHS U01 CA083180NIEHS NIH HHS P30 ES010126
6 · The paper itself
Abstract
backgroundRecent genome-wide association studies (GWAS) have identified new susceptibility loci for melanoma, but their associations with multiple primary melanoma (MPM) are unclear.
methodsWe investigated the associations of 69 SNPs in 39 GWAS-identified loci with odds of MPM relative to single primary melanoma in the international, population-based Genes, Environment, and Melanoma study. Per-minor-allele ORs and 95% confidence intervals (CI) for individuals with MPM "cases" (n = 1,205) relative to single primary melanoma "controls" (n = 2,458) were estimated using multivariable logistic regression, and polygenic risk scores (PRS) were calculated and weighted based on a 2020 GWAS meta-analysis (57 of the 68 independent GWAS SNPs available).
resultsThirteen SNPs in 11 gene regions (PARP1, CYP1B1/RMDN3, TERT, RAPGEF5, TYRP1, MTAP, CDKN2A/CDKN2B, KLF4, TYR, SOX6, and ASIP) were statistically significantly associated (P < 0.05) with MPM adjusting for age, sex, age-by-sex interaction, and study center. The highest versus lowest PRS quintile was associated with a 2.81-fold higher odds of MPM (95% CI, 2.10-3.78; P = 7.5 × 10-13); this association was attenuated but remained statistically significant after excluding SNPs individually associated with MPM (OR = 1.75, 95% CI, 1.32-2.31).
conclusionsInherited genetic variants spanning 11 gene regions were independently associated with MPM. Nonsignificant SNPs were associated with MPM when aggregated into a PRS, indicating that their cumulative effect may influence MPM risk despite lacking individual statistical significance in our study population. IMPACT: Our findings provide additional evidence that these loci are associated with melanoma risk and estimate the magnitude of their genetic effect on subsequent (multiple) primary melanoma risk.
Indexed as
MelanomaNeoplasms, Multiple PrimaryPolymorphism, Single NucleotideSkin NeoplasmsAdultAgedCase-Control StudiesFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHumansKruppel-Like Factor 4MaleMiddle AgedKLF4 protein, humanKruppel-Like Factor 4
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Association of Inherited Genetic Variants with Multiple Primary Melanoma. · full record | OpenQuestion